Showing results (241-250 of 334) with videos related to
Sort By:
Pageof 34
European Heart Journal|November 30, 2013
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges, Salim Yusuf, Amir Attaran, et al.Open Heart|December 19, 2025
Pooled randomised QUARTET trials assessing effectiveness of a single pill for hypertensionSimone Marschner, Mark D Huffman, Desi Quintans, et al.Neuroimage|January 8, 2017
Opioid suppression of conditioned anticipatory brain responses to breathlessnessAnja Hayen, Vishvarani Wanigasekera, Olivia K Faull, et al.Journal of Human Hypertension|July 4, 2026
Patient out-of-pocket costs for antihypertensive single pill combination products with cost capsCatherine G Derington, Kyle Tong, Joshua A Jacobs, et al.Cerebrovascular Diseases (Basel, Switzerland)|May 25, 2026
Blood pressure lowering for the prevention of REcurrent stroke and Cardiovascular outcomes After acute intracerebral haemorrhage: protocol for an individual Participant data meta-analysis of randomised controlled trials (RECAP-ICH)M J Velasco, Yijie Gao, Shitian Li, et al.The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.Journal of Hypertension|March 4, 2016
Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetesYoichiro Hirakawa, Hisatomi Arima, Ruth Webster, et al.Journal of the American Heart Association|January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisClare Arnott, Qiang Li, Amy Kang, et al.Journal of Clinical Hypertension (Greenwich, Conn.)|August 21, 2020
Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and costAbdul Salam, Mark D Huffman, Raju Kanukula, et al.Cancer|August 17, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyJørn Herrstedt, Hyman B Muss, David G Warr, et al.Pageof 34